februari 21, 2024

Ectin Research emphasizes strong preclinical development of MFA-370 and extensive business development activities in Q4 2023 report

Ectin Research has reported strong preclinical development of MFA-370 – including new animal data demonstrating a growth-inhibiting and tumor-shrinking effect on triple-negative breast cancer tumors – and intensive ongoing business development activities in its Year-End 2023 Report.

Read the full report in Swedish here: https://www.ectinresearch.com/finansiella-rapporter/

CEO Anna Sjöblom-Hallén: “During 2023 we have focused on two areas: financing the company’s operations and value-creating preclinical development work.

“Throughout the year we have participated in a wide range of industry conferences which have given us a good picture of the addressable financial market and how we can best promote interest in the future. This work will continue in 2024.

“Our second focus area during the year has been preclinical development and we have achieved several important milestones. New findings suggest that even the aggressive cancers triple-negative breast cancer as well as the rare disease uveal melanoma can potentially be treated with MFA-370.

In conclusion, I believe that our work in 2023 has equipped us well for the future. I look forward to continuing work towards the goal of being able to offer patients effective cancer treatments”.

Ectin Research’s MFA-370 is a repurposed combination therapy for cancer tumours planned to be taken as a simple oral tablet with few if any side effects. In previous preclinical studies it has achieved antiproliferative results demonstrating how it has significantly dampened the growth of e.g. bladder, breast, colorectal and prostate tumour cells.